Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Folic Acid Tablet Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

NCT04393298
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ginisortamab, trifluridine/tipiracil, mFOLFOX6
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

NCT01913639
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Regorafenib, 5-Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

NCT00967616
View directory record Official record
Conditions
Colorectal Cancer, Neoplasms, Colorectal
Interventions
CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

NCT00112918
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Bevacizumab, Capecitabine, 5-Fluorouracil (5-FU), Leucovorin calcium, Oxaliplatin
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3,451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Sep 6, 2026, 11:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

NCT00923273
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
FDG-PET, Pemetrexed, Sirolimus, Vitamin B12, Folic acid tablets, Dexamethasone tablets
Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women

NCT02683369
View directory record Official record
Conditions
Non-anemic Iron Deficiency
Interventions
Blood Builder®/Iron Response®
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Folic Acid Supplementation in Women of Child Bearing Age

NCT01841658
View directory record Official record
Conditions
Obesity
Interventions
Folic acid
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)

NCT00726713
View directory record Official record
Conditions
Type 2 Diabetic Peripheral Neuropathy (DPN)
Interventions
Metanx (a medical food), Metanx placebo
Other
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
25 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 6, 2026, 11:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature

NCT05067998
View directory record Official record
Conditions
Anxiety Disorders and Symptoms, Fibromyalgia, Arthritis, Chronic Pain, Hypertension,Essential
Interventions
IV Vitamin Infused Therapy Treatment, Herbal medicine
Dietary Supplement · Drug
Lead sponsor
Faith A. Richardson
Other
Eligibility
21 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dover, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 6, 2026, 11:41 PM EDT
Recruiting Phase 1 Interventional

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT05719558
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP1002, Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Trifluridine-Tipiracil, Pembrolizumab, Pemetrexed, Carboplatin, Ramucirumab, Docetaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional

A Multivitamin Comparison Study in Kidney Transplant Recipients.

NCT00217100
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
Multivitamin, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

NCT01482962
View directory record Official record
Conditions
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Interventions
Alisertib, Pralatrexate, Gemcitabine, Romidepsin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 6, 2026, 11:41 PM EDT
Recruiting Phase 2 Interventional

ALL Backbone in AYAs

NCT07227584
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
Interventions
Blinatumomab, Oncaspar, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Mercaptopurine, Methotrexate, Vincristine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 51 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

NCT01289821
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

A Study of Serum Folate Levels in Patients Treated With Olaparib

NCT04024254
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Folic Acid Deficiency
Interventions
Folic Acid Tablet
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 6, 2026, 11:41 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

NCT00502567
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
AZD2171, FOLFOX, Pemetrexed, Irinotecan (administered with & without Cetuximab), Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cooling Strategies for Older Adults in the Heat

NCT06349616
View directory record Official record
Conditions
Aging
Interventions
Intermittent cold-water hand and forearm immersion, No intermittent cold-water hand and forearm immersion
Other
Lead sponsor
Penn State University
Other
Eligibility
65 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 6, 2026, 11:41 PM EDT
Active, not recruiting Phase 1 Interventional

First in Human Study of AZD9592 in Solid Tumors

NCT05647122
View directory record Official record
Conditions
Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
Interventions
AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • North Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 6, 2026, 11:41 PM EDT
Completed No phase listed Observational Results available

PET/CT Imaging Companion Study To ACTG A5314

NCT02312219
View directory record Official record
Conditions
HIV, Inflammation, Atherosclerosis
Interventions
Folic Acid, Placebo, Low Dose Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 6, 2026, 11:41 PM EDT
Terminated Phase 2 Interventional

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

NCT04141995
View directory record Official record
Conditions
Pancreas Cancer, Adenocarcinoma of the Pancreas
Interventions
Digoxin, 5Fluorouracil, Calcium Leucovorin, Irinotecan, Oxaliplatin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 6, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

NCT03374254
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Pembrolizumab, Binimetinib, Oxaliplatin, Leucovorin, 5-Fluorouracil [5-FU], Irinotecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 6, 2026, 11:41 PM EDT